The University of Texas MD Anderson Cancer Center brings its signature Making Cancer History® seminar to Midland, for the first time, 11:30 a.m. to 1:30 p.m., Tuesday, April 12, at the Midland Country Club, 6101 N. Highway 349.
The American Society of Clinical Oncology (ASCO) will recognize two physician-scientists from The University of Texas MD Anderson Cancer Center with two of its highest distinctions at its annual meeting in Chicago.
A new study from The University of Texas MD Anderson Cancer Center evaluating the use of neurofeedback found a decrease in the experience of chronic pain and increase quality of life in patients with neuropathic pain.
Consuming a diet with a high glycemic index, a classification of how rapidly carbohydrates elevate blood sugar levels, was independently associated with an increased risk of developing lung cancer in non-Hispanic whites, according to a new epidemiologic study from The University of Texas MD Anderson Cancer Center.
PGK1, a glycolytic enzyme, has been found to play a role in coordinating cellular processes crucial to cancer metabolism and brain tumor formation, according to results published in today’s online issue of Molecular Cell.
The University of Texas MD Anderson Cancer Center brings its Making Cancer History® seminar to Indian Wells, Calif. on Tuesday, March 8, at the Renaissance Indian Wells Resort & Spa, 44400 Indian Wells Lane.
A study that revealed new findings about prostate cells may point to future strategies for treating aggressive and therapy-resistant forms of prostate cancer.
The University of Texas MD Anderson Cancer Center was awarded $14 million this week from the Cancer Prevention and Research Institute of Texas (CPRIT) for the recruitment of three cancer scientists.
Current staging system is inadequate; for the first time, research proves that staging based on nasopharyngeal “N” categories offers more predictive value
ONC201, an anti-cancer drug that triggers cell death in various tumor types, may have clinical potential for some blood cancers including mantel cell lymphoma (MCL) and acute myeloid leukemia (AML), according to a recent clinical study.
The University of Texas MD Anderson Cancer Center will share novel research findings, cancer prevention tips and advances driven by the institution’s Moon Shots Program at an educational event in Palm Beach, Feb. 20 at The Colony Hotel, 155 Hammon Ave.
Researchers at The University of Texas MD Anderson Cancer will share in a funding award of $13.4 million with hopes of answering one of the biggest questions in the current management of breast cancer: do women with the earliest form of the disease, ductal carcinoma in situ (DCIS), need invasive surgery?
An international collaborative study has revealed detailed new information about diffuse glioma, the most common type of tumor found in some 80 percent of adult brain cancer patients, raising hopes that better understanding of these disease groups may aid improved clinical outcomes.
In response to low national vaccination rates for the human papillomavirus (HPV), The University of Texas MD Anderson Cancer Center has joined with the 68 other National Cancer Institute (NCI)-designated cancer centers in issuing a statement calling for increased HPV vaccination for the prevention of cancer.
A new procedure developed by surgeons at The University of Texas MD Anderson Cancer Center improves the accuracy of axillary staging and pathologic evaluation in clinically node-positive breast cancer, and reduces the need for a more invasive procedure with debilitating complications.
Treatment of multiple sclerosis (MS) and other inflammatory diseases may benefit by new findings from a study that identified potential therapeutic targets for a devastating disease striking some 2.3 million people worldwide.
The immunotherapy platform at The University of Texas MD Anderson Cancer Center and the global biopharmaceutical company AbbVie will join forces to find new ways to unleash the immune system’s potential to fight cancer.
Findings from a new study reveal that PARP inhibitors, an emerging class of drugs being studied in cancer clinical trials, may be enhanced by combining them with inhibitors targeting an oncogene known as c-MET which is overexpressed in many cancers.
The University of Texas MD Anderson Cancer Center today announced that it has entered into a collaborative research and development agreement with Enumeral Biomedical Holdings Inc.
In cancer, cell signaling pathways are the critical chain of events that can either quash or quicken disease progression.
Kymab, a leading human monoclonal antibody biopharmaceutical company, and The University of Texas MD Anderson Oncology Research for Biologics and Immunotherapy Translation (ORBIT) unit today announced a strategic cancer drug discovery and development alliance.
The high amounts of dietary sugar in the typical Western diet may increase the risk of breast cancer and metastasis to the lungs, according to a study at The University of Texas MD Anderson Cancer Center.
Immune suppressor cells called MDSCs (myeloid-derived suppressor cells) may be important in developing treatments for advanced prostate cancer, according to a study at The University of Texas MD Anderson Cancer Center.
Pancreatic cancer tumors spill their molecular secrets into the blood stream, shedding their complete DNA and RNA wrapped inside protective lipid particles that make them ripe for analysis with a liquid biopsy, researchers at The University of Texas MD Anderson Cancer Center report online at the Annals of Oncology.
Craig Jordan, Ph.D., a breast cancer research pioneer known for his development of the therapeutic drug tamoxifen, has been named a recipient of the Sir James Black Award from the British Pharmacological Society.
Patients with lymphoma or myeloma and their caregivers will have access to leading experts in this field of cancer during an upcoming symposium to be held Jan. 9 in Houston.
Postponing the start of adjuvant chemotherapy for more than 90 days following surgery may significantly increase risk of death for breast cancer patients, particularly those with triple-negative breast cancer (TNBC), according to a new study from The University of Texas MD Anderson Cancer Center.
Treatment modality is also the most expensive in younger patients, MD Anderson study finds
A first-in-human Phase I study of multiple myeloma patients combined expanded cord blood-derived natural killer cells with transplantation of a patient’s own stem cells and high-dose chemotherapy with little or none of the side effects seen with current treatments.
Scientists have shown for the first time why loss of the enzyme CD73 in human cancer promotes tumor progression.
A multi-center, international, randomized, Phase III study of older untreated patients with chronic lymphocytic leukemia (CLL) demonstrated that ibrutinib, a kinase inhibitor, is significantly more effective than traditional chemotherapy with chlorambucil.
Depression is a significant predictor of five-year survival and recurrence in head and neck cancer patients, according to a new study from The University of Texas MD Anderson Cancer Center.
Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a collaboration focused on developing innovative medicines for pancreatic ductal adenocarcinoma (PDAC).
The optimal treatment approach for most women with breast implant-associated anaplastic large-cell lymphoma (BI-ALCL) is complete surgical excision of the implant and surrounding capsule, according to an international study led by researchers at The University of Texas MD Anderson Cancer Center.
Distinguished contributions to understanding p53 tumor suppression in stem cells and breakthrough advances in treating breast cancer have earned two scientists at The University of Texas MD Anderson Cancer Center membership in a notable association of scholars.
A crucial tumor-thwarting gene protects an immune attack against lung cancer by blocking the key to an off switch on T cells, the customized warriors of the immune system, a team led by researchers at The University of Texas MD Anderson Cancer Center reports in the Journal of the National Cancer Institute.
The University of Texas MD Anderson Cancer Center was awarded more than $22 million in research grants this week from the Cancer Prevention and Research Institute of Texas (CPRIT).
Codiak BioSciences, Inc. announced today the closing of the first portion of a planned $80-plus million Series A and B financing. The company also executed license and sponsored research agreements with The University of Texas MD Anderson Cancer Center in Houston.
Andy Sabin, of East Hampton, N.Y., has committed $30 million — the philanthropist’s largest grant to date — to support research at The University of Texas MD Anderson Cancer Center.
Cetuximab, marketed as Erbitux®, is one of the key therapies for metastatic colorectal cancer. Yet the cancer still returns in some patients, shortening overall survival.
A study at The University of Texas MD Anderson Cancer Center may explain why chemotherapy drugs such as gemcitabine are not effective for many pancreatic cancer patients, and perhaps point to new approaches to treatment including enhancing gemcitabine’s ability to stop tumor growth.
Former Secretary of State Condoleezza Rice is the honoree of A Conversation With a Living Legend®, benefiting The University of Texas MD Anderson Cancer Center, Tuesday Dec. 1 at the Hilton Anatole in Dallas.
Diets high in meat may lead to an increased risk of developing renal cell carcinoma (RCC) through intake of carcinogenic compounds created by certain cooking techniques, such as barbecuing and pan-frying.
A team of scientists, led by researchers at The University of Texas MD Anderson Cancer Center and University of California, San Diego Moores Cancer Center, report that a genetic biomarker called loss of heterozygosity or LOH is able to predict which patients with premalignant mouth lesions are at highest risk of developing oral cancer.
CytomX Therapeutics (Nasdaq: CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today entered into a collaboration with The University of Texas MD Anderson Cancer Center to research Probody-enabled chimeric antigen receptor natural killer (CAR-NK) cell therapies, to be known as ProCAR-NK cell therapies.
MD Anderson’s Moon Shots Program, an unprecedented effort and novel organizational model designed to more rapidly convert scientific discoveries into life-saving advances, has expanded its targets, adding several of the most intractable cancers to its campaign.
It’s no surprise that people enjoy warm places like Hawaii but may suffer in hostile locales such as Antarctica. A tumor suppressor gene called PTEN is similar in that it is affected by the microenvironments of certain bodily organs to which it travels.
An analysis of an international, cooperative-led trial of patients with locally advanced non-small cell lung cancer (NSCLC) has shown that those who received intensity modulated radiation therapy (IMRT) had less severe lung toxicity and were able to better tolerate their chemotherapy, compared to patients who received 3–dimensional conformal radiation therapy (3-D CRT).
Scientists have shown why a drug widely used to treat chemotherapy-induced anemia in ovarian and breast cancer patients also may shorten survival times in some patients by inadvertently stimulating tumor growth.
OncoResponse, an immuno-oncology antibody discovery company, has been launched jointly by The University of Texas MD Anderson Cancer Center and Theraclone Sciences.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right